5 Stocks Boosting The Health Services Industry Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

One out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading down 30 points (-0.2%) at 15,089 as of Monday, May 13, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,245 issues advancing vs. 1,704 declining with 112 unchanged.

The Health Services industry currently sits up 0.3% versus the S&P 500, which is unchanged. Top gainers within the industry include St Jude Medical ( STJ), up 2.3%, Stryker Corporation ( SYK), up 0.8% and Zimmer Holdings ( ZMH), up 0.8%. On the negative front, top decliners within the industry include Agilent Technologies ( A), down 1.97, Fresenius Medical Care AG & Co. KGaA ( FMS), down 1.43 and Grifols ( GRFS), down 0.95.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today:

5. Boston Scientific ( BSX) is one of the companies pushing the Health Services industry higher today. As of noon trading, Boston Scientific is up $0.30 (3.55) to $8.75 on heavy volume Thus far, 18.4 million shares of Boston Scientific exchanged hands as compared to its average daily volume of 18.2 million shares. The stock has ranged in price between $8.39-$8.84 after having opened the day at $8.40 as compared to the previous trading day's close of $8.45.

Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. Boston Scientific has a market cap of $11.2 billion and is part of the health care sector. Shares are up 44.9% year to date as of the close of trading on Friday. Currently there are 4 analysts that rate Boston Scientific a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Boston Scientific as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full Boston Scientific Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

4. As of noon trading, Covidien ( COV) is up $0.26 (0.39) to $66.44 on light volume Thus far, 545,533 shares of Covidien exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $65.82-$66.59 after having opened the day at $65.84 as compared to the previous trading day's close of $66.18.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Covidien has a market cap of $30.9 billion and is part of the health care sector. The company has a P/E ratio of 17.0, below the S&P 500 P/E ratio of 17.7. Shares are up 13.9% year to date as of the close of trading on Friday. Currently there are 14 analysts that rate Covidien a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Covidien Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

3. As of noon trading, Medtronic ( MDT) is up $0.24 (0.49) to $49.41 on light volume Thus far, 1.5 million shares of Medtronic exchanged hands as compared to its average daily volume of 4.3 million shares. The stock has ranged in price between $48.90-$49.59 after having opened the day at $48.90 as compared to the previous trading day's close of $49.17.

Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. Medtronic has a market cap of $49.5 billion and is part of the health care sector. The company has a P/E ratio of 14.9, below the S&P 500 P/E ratio of 17.7. Shares are up 19.1% year to date as of the close of trading on Friday. Currently there are 6 analysts that rate Medtronic a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Medtronic as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, increase in net income and attractive valuation levels. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Medtronic Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

2. As of noon trading, Abbott Laboratories ( ABT) is up $0.37 (1.02) to $36.54 on light volume Thus far, 2.5 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 7.5 million shares. The stock has ranged in price between $36.04-$36.57 after having opened the day at $36.05 as compared to the previous trading day's close of $36.17.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. Abbott Laboratories has a market cap of $56.4 billion and is part of the health care sector. The company has a P/E ratio of 9.4, below the S&P 500 P/E ratio of 17.7. Shares are up 10.5% year to date as of the close of trading on Friday. Currently there are 9 analysts that rate Abbott Laboratories a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Abbott Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, a generally disappointing performance in the stock itself and feeble growth in the company's earnings per share. Get the full Abbott Laboratories Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

1. As of noon trading, Express Scripts ( ESRX) is up $0.62 (1.02) to $62.02 on light volume Thus far, 1.9 million shares of Express Scripts exchanged hands as compared to its average daily volume of 5.8 million shares. The stock has ranged in price between $61.40-$62.07 after having opened the day at $61.66 as compared to the previous trading day's close of $61.40.

Express Scripts Holding Company provides a range of pharmacy benefit management (PBM) services primarily in the United States and Canada. It offers healthcare management and administration services on behalf of its clients. Express Scripts has a market cap of $50.3 billion and is part of the health care sector. The company has a P/E ratio of 36.4, above the S&P 500 P/E ratio of 17.7. Shares are up 14.0% year to date as of the close of trading on Friday. Currently there are 12 analysts that rate Express Scripts a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Express Scripts as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Express Scripts Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

More from Markets

Dow Logs Eighth Straight Drop as Stocks Slump

Dow Logs Eighth Straight Drop as Stocks Slump

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

U.S. Banks Pass Fed 'Stress Test' With Room for Dividends, Buybacks

U.S. Banks Pass Fed 'Stress Test' With Room for Dividends, Buybacks

U.S. Drillers at Mercy of Iran, Saudi Production Spat as OPEC Meeting Begins

U.S. Drillers at Mercy of Iran, Saudi Production Spat as OPEC Meeting Begins

Comcast's Brian Roberts vs. Disney's Bob Iger: Which Titan Will Nab Fox?

Comcast's Brian Roberts vs. Disney's Bob Iger: Which Titan Will Nab Fox?